Advertisement
To access a live audio webcast of either presentation, investors and otherinterested parties may log on to the investor relations page of InterMune'scorporate website at http://www.intermune.com. The company recommends loggingon to the site 15 minutes prior to the start of the presentations in order toregister or download any necessary software.
Advertisement
About InterMune
InterMune is a biotechnology company focused on the research, developmentand commercialization of innovative therapies in pulmonology and hepatology.InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis(IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolioincludes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as apossible therapeutic candidate for the treatment of patients with IPF and aresearch program focused on small molecules for pulmonary disease. Thehepatology portfolio includes the HCV protease inhibitor compound ITMN-191(referred to as R7227 at Roche) in Phase 1b, a second-generation HCV proteaseinhibitor research program, and a research program evaluating a new target inhepatology. For additional information about InterMune and its R&D pipeline,please visit http://www.intermune.com.
SOURCE InterMune, Inc.